NICE previously rejected Leqembi and Kisunla for NHS coverage in August and October 2024, respectively.
Category: GLP-1 News
J&J drops Phase III MDD programme due to lack of efficacy
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed…
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance – U.S. News & World Report
Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance U.S. News & World Report
Are weight-loss drugs like Ozempic a forever medicine? Vikrant Shrotriya of Novo Nordisk India reacts – Business Today
Are weight-loss drugs like Ozempic a forever medicine? Vikrant Shrotriya of Novo Nordisk India reacts Business Today
New Discovery Promises Weight Loss Without Ozempic’s Side Effects – Newsweek
New Discovery Promises Weight Loss Without Ozempic’s Side Effects Newsweek
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment…
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD
The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment…
Pfizer appoints former J&J executive to lead obesity drug development – Reuters
Pfizer appoints former J&J executive to lead obesity drug development Reuters
Does ‘Oatzempic’ Help You Lose Weight? – Verywell Health
Does ‘Oatzempic’ Help You Lose Weight? Verywell Health
Industry Voices—The GLP-1 status quo is no longer acceptable, but it is changeable. – Fierce healthcare
Industry Voices—The GLP-1 status quo is no longer acceptable, but it is changeable. Fierce healthcare